The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis

Stella A Glasmacher; Patrick Ka Kearns; Zackary Hassan; Peter Connick; Simone Tauber; Kathrin Reetz; Peter Foley; Siddharthan Chandran

doi:10.1016/j.msard.2022.103837

The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis

Stella A Glasmacher, Patrick Ka Kearns, Zackary Hassan, Peter Connick, Simone Tauber, Kathrin Reetz, Peter Foley, Siddharthan Chandran

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	103837
Journal	Multiple Sclerosis and Related Disorders
Volume	63
DOIs	https://doi.org/10.1016/j.msard.2022.103837
Publication status	Published - 30 Apr 2022

Access to Document

10.1016/j.msard.2022.103837

FMS-hd-mnscrpt-MSARD_rev_final-cleanAccepted author manuscript, 114 KBLicence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S2211034822003492

Cite this

@article{a8255cd803f14c5e9f66ad942ca3fa45,

title = "The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis",

author = "Glasmacher, \{Stella A\} and Kearns, \{Patrick Ka\} and Zackary Hassan and Peter Connick and Simone Tauber and Kathrin Reetz and Peter Foley and Siddharthan Chandran",

note = "Funding Information: PKAK is funded by an ECAT/Wellcome PhD Studentship. SC acknowledges the Euan MacDonald Centre for Motor Neurone Research and the UK Dementia Research Institute partner funders: the Medical Research Council, Alzheimer's Research UK and the Alzheimer's Society. Funding Information: FutureMS is funded by a grant from the Scottish Funding Council to Precision Medicine Scotland Innovation Centre (PMS IC) and Biogen Idec Ltd Insurance. Biogen had no role in the study design, collection, interpretation, analysis of data or writing of the manuscript. Funding Information: Insurance was provided by the Co-Sponsors: NHS Lothian and the University of Edinburgh. We acknowledge support and funding from the MS Society UK Centre of Excellence and the Anne Rowling Clinic. The University 3 T MRI Research scanner in RIE is funded by the Wellcome Trust (104,916/Z/14/Z), Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir Maxwell Research Fund, Edinburgh Imaging and University of Edinburgh. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = apr,

day = "30",

doi = "10.1016/j.msard.2022.103837",

language = "English",

volume = "63",

pages = "103837",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis

AU - Glasmacher, Stella A

AU - Kearns, Patrick Ka

AU - Hassan, Zackary

AU - Connick, Peter

AU - Tauber, Simone

AU - Reetz, Kathrin

AU - Foley, Peter

AU - Chandran, Siddharthan

N1 - Funding Information: PKAK is funded by an ECAT/Wellcome PhD Studentship. SC acknowledges the Euan MacDonald Centre for Motor Neurone Research and the UK Dementia Research Institute partner funders: the Medical Research Council, Alzheimer's Research UK and the Alzheimer's Society. Funding Information: FutureMS is funded by a grant from the Scottish Funding Council to Precision Medicine Scotland Innovation Centre (PMS IC) and Biogen Idec Ltd Insurance. Biogen had no role in the study design, collection, interpretation, analysis of data or writing of the manuscript. Funding Information: Insurance was provided by the Co-Sponsors: NHS Lothian and the University of Edinburgh. We acknowledge support and funding from the MS Society UK Centre of Excellence and the Anne Rowling Clinic. The University 3 T MRI Research scanner in RIE is funded by the Wellcome Trust (104,916/Z/14/Z), Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir Maxwell Research Fund, Edinburgh Imaging and University of Edinburgh. Publisher Copyright: © 2022

PY - 2022/4/30

Y1 - 2022/4/30

U2 - 10.1016/j.msard.2022.103837

DO - 10.1016/j.msard.2022.103837

M3 - Article

SN - 2211-0348

VL - 63

SP - 103837

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -